Literature DB >> 34341573

Flawed ivermectin preprint highlights challenges of COVID drug studies.

Sara Reardon.   

Abstract

Entities:  

Keywords:  Public health; Publishing; Research data; SARS-CoV-2

Year:  2021        PMID： 34341573     DOI： 10.1038/d41586-021-02081-w

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  2 in total

1.  The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.

Authors:  Leon Caly; Julian D Druce; Mike G Catton; David A Jans; Kylie M Wagstaff
Journal:  Antiviral Res       Date:  2020-04-03       Impact factor: 5.970

2.  Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines.

Authors:  Andrew Bryant; Theresa A Lawrie; Therese Dowswell; Edmund J Fordham; Scott Mitchell; Sarah R Hill; Tony C Tham
Journal:  Am J Ther       Date:  2021-06-21       Impact factor: 2.688
  2 in total
  14 in total

1.  COVID-19 in Missouri 2020-2021: A Perspective on Origins, Spread & Controversies, Part I.

Authors:  David S McKinsey; Joel P McKinsey; Neil B Hampson; Maithe Enriquez
Journal:  Mo Med       Date:  2022 Mar-Apr

Review 2.  Pharmacological interventions to prevent Covid-19 disease: A rapid review.

Authors:  Karen Cardwell; Eamon O Murchu; Paula Byrne; Natasha Broderick; Kieran A Walsh; Sinéad M O'Neill; Susan M Smith; Patricia Harrington; Máirín Ryan; Michelle O'Neill
Journal:  Rev Med Virol       Date:  2021-09-28       Impact factor: 11.043

3.  Promoting constructive feedback on preprints with the FAST principles.

Authors:  Sandra Franco Iborra; Jessica Polka; Iratxe Puebla
Journal:  Elife       Date:  2022-04-27       Impact factor: 8.713

4.  Ivermectin for COVID-19: Addressing Potential Bias and Medical Fraud.

Authors:  Andrew Hill; Manya Mirchandani; Victoria Pilkington
Journal:  Open Forum Infect Dis       Date:  2022-01-17       Impact factor: 3.835

Review 5.  Formulating Hypotheses for Different Study Designs.

Authors:  Durga Prasanna Misra; Armen Yuri Gasparyan; Olena Zimba; Marlen Yessirkepov; Vikas Agarwal; George D Kitas
Journal:  J Korean Med Sci       Date:  2021-12-27       Impact factor: 2.153

Review 6.  Ivermectin and the Integrity of Healthcare Evidence During COVID-19.

Authors:  Dónal P O'Mathúna
Journal:  Front Public Health       Date:  2022-03-01

7.  The new normal? Redaction bias in biomedical science.

Authors:  David Robert Grimes; James Heathers
Journal:  R Soc Open Sci       Date:  2021-12-01       Impact factor: 2.963

8.  Safety and efficacy of fluvoxamine in COVID-19 ICU patients: An open label, prospective cohort trial with matched controls.

Authors:  Martina Calusic; Robert Marcec; Lea Luksa; Ivan Jurkovic; Natasa Kovac; Slobodan Mihaljevic; Robert Likic
Journal:  Br J Clin Pharmacol       Date:  2021-12-01       Impact factor: 3.716

Review 9.  COVID-19 and the promise of small molecule therapeutics: Are there lessons to be learnt?

Authors:  Wei Shen Ho; Ruirui Zhang; Yeong Lan Tan; Christina Li Lin Chai
Journal:  Pharmacol Res       Date:  2022-04-01       Impact factor: 10.334

Review 10.  Drug safety of frequently used drugs and substances for self-medication in COVID-19.

Authors:  Daniela Baracaldo-Santamaría; Santiago Pabón-Londoño; Luis Carlos Rojas-Rodriguez
Journal:  Ther Adv Drug Saf       Date:  2022-04-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.